Humana (HUM) experienced a stock loss of 34% in the past year and recent unusual options activity. However, it maintained a bullish stance among hedge funds, earned a 2024 Great Place To Work Certification, and analysts anticipate it can return to $500 from its current level. Despite higher-than-expected medical care use and subsequent share price slide, Humana intends to uphold its guidance. It also recently expanded its value-based services in Florida and reaffirmed its commitment to improving health outcomes through strategic partnerships. A reported $398.70 average target price was unveiled following Q2 earnings that surpassed estimates. Yet, its stock was hampered by mixed Q1 2024 results, disappointing Medicare Advantage rates, and updated mental health guidelines. An increase in medical costs also raised concerns for 2024 forecasts. Humana remains committed to future growth by maintaining EPS guidance, and positive insights were given regarding its strategic operations and potential. However, there is speculation about the healthy status of Humana shares, with some investors anticipating further decline due to higher costs and potential security fraud lawsuits.
Humana HUM News Analytics from Thu, 18 Jan 2024 08:00:00 GMT to Sun, 29 Sep 2024 10:30:00 GMT -
Rating 3
- Innovation -2
- Information 7
- Rumor -1
